Serum omentin-1 level in patients with benign prostatic hyperplasia

Abstract

Backgroud: To evaluate the relationship between omentin-1 and benign prostatic hyperplasia (BPH). BPH is the most common urological disease in elderly men worldwide. Lower serum omentin-1 levels were reported to be negatively associated with the incidence of inflammation, diabetes, obesity and metabolic syndrome, which all play a role in the development of BPH. To the best of our knowledge, the relationship between omentin-1 and BPH has not been investigated previously. Methods: A total of 70 males participated in this study, including forty patients diagnosed with BPH and thirty healthy males. The anthropometric measurements and the biochemical parameters were measured in this study. We evaluated serum omentin-1 levels and the correlation with those data. We also test the gene expression of IL-8, IL-18 in BPH group using the TURP tissues. Results: The serum omentin-1 levels were lower in the BPH patients than in the control group (27.95 ± 4.18 versus 32.03 ± 5.46, p < 0.001). The general characteristics and biochemical parameters were investigated, and a negative correlation was found between serum omentin-1 levels and BMI in the BPH group (r = − 0.391, p = 0.013) as well as the whole group (r = − 0.457, p < 0.001). Multiple-factor binary regression analysis revealed that serum omentin-1was a protective factor of BPH development. Furthermore, lower serum omentin-1 levels were associated with higher mRNA expression of IL-8 or IL-18 in the BPH group. Conclusion: Omentin-1 may suppress the development of BPH and Lower serum omentin-1 levels in BPH patients might associated with higher prostate volume and higher IL-8 and IL-18 expression levels in their prostatic cells.

Tissue immunoexpression of IL-6 and IL-18 in aging men with BPH and MetS and their relationship with lipid parameters and gut microbiota - derived short chain fatty acids

“…Referring this to the results obtained by us, it can be stated that in the case of the prostate tissue collected from BPH patients with MetS, the negative relationship between acetate and IL-18 does not reduce its cellular synthesis, which is observed as the highest percentage of IL-18 positive cells in the glandular epithelium of the prostate. The tissue expression of IL-18 was also confirmed in the study by He et al [ 67 ], in which its relationship with low values of omentin-1 – a hormone synthesised by adipose tissue, the reduced concentrations of which were observed, among others, was analysed in type 2 diabetes, obesity or cardiovascular diseases. It has also been proven that IL-18 significantly contributes to the development of inflammatory diseases or chronic inflammation in the course of BPH [ 67 ].…”

“…The tissue expression of IL-18 was also confirmed in the study by He et al [ 67 ], in which its relationship with low values of omentin-1 – a hormone synthesised by adipose tissue, the reduced concentrations of which were observed, among others, was analysed in type 2 diabetes, obesity or cardiovascular diseases. It has also been proven that IL-18 significantly contributes to the development of inflammatory diseases or chronic inflammation in the course of BPH [ 67 ]. The study by Lebel-Binay et al [ 68 ] analysed the secretion of IL-18 in the prostate tissue.…”

The Role of Omentin-1 in Cancers Development and Progression

“…The results showed that not only omentin-1 but also growth factors-HGF and VEGF-concentrations were significantly higher in the PC than in the BPH group. Studies by He et al indicated that lower serum omentin-1 levels were associated with mRNA overexpression of IL-8 and IL-18 in the BPH prostatic cells and higher prostate volume [77].…”

The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer

“…Several studies have shown that overweight and obese individuals had reduced concentrations of omentin, and its expression in visceral adipose tissue was significantly reduced than in lean individuals. Moreover, omentin concentration is inversely correlated with BMI and percent body fat [ 260 , 261 , 265 , 266 ]. An increase in serum omentin levels correlated with a decrease in serum CRP levels and suppression of TNF-α function, confirming the link between ITLN and inflammation [ 267 ].…”